|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2019. CA Cancer J Clin. 69:7–34. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Wong MC, Goggins WB, Wang HH, Fung FD,
Leung C, Wong SY, Ng CF and Sung JJ: Global incidence and mortality
for prostate cancer: Analysis of temporal patterns and trends in 36
countries. Eur Urol. 70:862–874. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Tsao CK, Galsky MD and Oh WK: Docetaxel
for metastatic Hormone-sensitive prostate cancer: Urgent need to
minimize the risk of neutropenic fever. Eur Urol. 70:707–708. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Fizazi K, Ulys A, Sengeløv L, Moe M,
Ladoire S, Thiery- Vuillemin A, Flechon A, Guida A, Bellmunt J,
Climent MA, et al: A randomized, double-blind, placebo-controlled
phase II study of maintenance therapy with tasquinimod in patients
with metastatic castration-resistant prostate cancer responsive to
or stabilized during first-line docetaxel chemotherapy. Ann Oncol.
28:2741–2746. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Thadani-Mulero M, Portella L, Sun S, Sung
M, Matov A, Vessella RL, Corey E, Nanus DM, Plymate SR and
Giannakakou P: Androgen receptor splice variants determine taxane
sensitivity in prostate cancer. Cancer Res. 74:2270–2282. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ploussard G, Terry S, Maillé P, Allory Y,
Sirab N, Kheuang L, Soyeux P, Nicolaiew N, Coppolani E, Paule B, et
al: Class III beta-tubulin expression predicts prostate tumor
aggressiveness and patient response to docetaxel-based
chemotherapy. Cancer Res. 70:9253–9264. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Zhu Y, Liu C, Nadiminty N, Lou W, Tummala
R, Evans CP and Gao AC: Inhibition of ABCB1 expression overcomes
acquired docetaxel resistance in prostate cancer. Mol Cancer Ther.
12:1829–1836. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Chen H, Li H and Chen Q: INPP4B reverses
docetaxel resistance and epithelial-to-mesenchymal transition via
the PI3K/Akt signaling pathway in prostate cancer. Biochem Biophys
Res Commun. 477:467–4672. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
De Bessa Garcia SA, Pavanelli AC, Cruz E
Melo N and Nagai MA: Prostate apoptosis response 4 (PAR4)
expression modulates WNT signaling pathways in MCF7 breast cancer
cells: A possible mechanism underlying PAR4-mediated docetaxel
chemosensitivity. Int J Mol Med. 39:809–818. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Codony-Servat J, Marín-Aguilera M, Visa L,
García-Albéniz X, Pineda E, Fernández PL, Filella X, Gascón P and
Mellado B: Nuclear factor-kappa B and interleukin-6 related
docetaxel resistance in castration-resistant prostate cancer.
Prostate. 73:512–521. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Marín-Aguilera M, Codony-Servat J, Reig Ò,
Lozano JJ, Fernández PL, Pereira MV, Jiménez N, Donovan M, Puig P
and Mengual L: Epithelial-to-mesenchymal transition mediates
docetaxel resistance and high risk of relapse in prostate cancer.
Mol Cancer Ther. 13:1270–1284. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Sotiriou C and Piccart MJ: Taking
gene-expression profiling to the clinic: When will molecular
signatures become relevant to patient care? Nat Rev Cancer.
7:545–553. 2007. View
Article : Google Scholar : PubMed/NCBI
|
|
13
|
Marín-Aguilera M, Codony-Servat J, Kalko
SG, Fernández PL, Bermudo R, Buxo E, Ribal MJ, Gascón P and Mellado
B: Identification of docetaxel resistance genes in
castration-resistant prostate cancer. Mol Cancer Ther. 11:329–339.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Irizarry RA, Hobbs B, Collin F,
Beazer-Barclay YD, Antonellis KJ, Scherf U and Speed TP:
Exploration, normalization, and summaries of high density
oligonucleotide array probe level data. Biostatistics. 4:249–264.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ritchie ME, Phipson B, Wu D, Hu Y, Law CW,
Shi W and Smyth GK: Limma powers differential expression analyses
for RNA-sequencing and microarray studies. Nucleic Acids Res.
43:e472015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wang L, Cao C, Ma Q, Zeng Q, Wang H, Cheng
Z, Zhu G, Qi J, Ma H, Nian H and Wang Y: RNA-seq analyses of
multiple meristems of soybean: Novel and alternative transcripts,
evolutionary and functional implications. BMC Plant Biol.
14:1692014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Tian Z, Wang C, Guo M, Liu X and Teng Z:
An improved method for functional similarity analysis of genes
based on Gene Ontology. BMC Syst Biol. 10 (Suppl 4):S1192016.
View Article : Google Scholar
|
|
18
|
Kanehisa M, Goto S, Sato Y, Furumichi M
and Tanabe M: KEGG for integration and interpretation of
large-scale molecular data sets. Nucleic Acids Res 40 (Database
Issue). D109–D114. 2012. View Article : Google Scholar
|
|
19
|
Huang da W, Sherman BT and Lempicki RA:
Systematic and integrative analysis of large gene lists using DAVID
bioinformatics resources. Nat Protoc. 4:44–57. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Franceschini A, Szklarczyk D, Frankild S,
Kuhn M, Simonovic M, Roth A, Lin J, Minguez P, Bork P, von Mering C
and Jensen LJ: STRING v9.1: Protein-protein interaction networks,
with increased coverage and integration. Nucleic Acids Res 41
(Database Issue). D808–D815. 2013.
|
|
21
|
Smoot ME, Ono K, Ruscheinski J, Wang PL
and Ideker T: Cytoscape 2.8: New features for data integration and
network visualization. Bioinformatics. 27:431–432. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Almeida D, Azevedo V, Silva A and Baumbach
J: PetriScape-A plugin for discrete Petri net simulations in
Cytoscape. J Integr Bioinform. 13:2842016. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Chin CH, Chen SH, Wu HH, Ho CW, Ko MT and
Lin CY: cytoHubba: Identifying hub objects and sub-networks from
complex interactome. BMC Syst Biol. 8 (Suppl 4):S112014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Tang Z, Li C, Kang B, Gao G, Li C and
Zhang Z: GEPIA: A web server for cancer and normal gene expression
profiling and interactive analyses. Nucleic Acids Res. 45:W98–W102.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Lin JZ, Wang ZJ, De W, Zheng M, Xu WZ, Wu
HF, Armstrong A and Zhu JG: Targeting AXL overcomes resistance to
docetaxel therapy in advanced prostate cancer. Oncotarget.
8:41064–41077. 2017.PubMed/NCBI
|
|
26
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Pozdeyev N, Berlinberg A, Zhou Q, Wuensch
K, Shibata H, Wood WM and Haugen BR: Targeting the NF-κB pathway as
a combination therapy for advanced thyroid cancer. PLoS One.
10:e01349012015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Mimeault M, Johansson SL and Batra SK:
Pathobiological implications of the expression of EGFR, pAkt, NF-κB
and MIC-1 in prostate cancer stem cells and their progenies. PLoS
One. 7:e319192012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Haralambieva IH, Ovsyannikova IG, Umlauf
BJ, Vierkant RA, Shane Pankratz V, Jacobson RM and Poland GA:
Genetic polymorphisms in host antiviral genes: Associations with
humoral and cellular immunity to measles vaccine. Vaccine.
29:8988–8997. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Xue Y, Rushton MD and Maringele L: A novel
checkpoint and RPA inhibitory pathway regulated by Rif1. PLoS
Genet. 7:e10024172011. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Croci DO and Salatino M: Tumor immune
escape mechanisms that operate during metastasis. Curr Pharm
Biotechnol. 12:1923–1936. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Slavin-Chiorini DC, Catalfamo M,
Kudo-Saito C, Hodge JW, Schlom J and Sabzevari H: Amplification of
the lytic potential of effector/memory CD8+ cells by vector-based
enhancement of ICAM-1 (CD54) in target cells: Implications for
intratumoral vaccine therapy. Cancer Gene Ther. 11:665–680. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Brat DJ, Bellail AC and Van Meir EG: The
role of interleukin-8 and its receptors in gliomagenesis and
tumoral angiogenesis. Neuro Oncol. 7:122–133. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Roumeguère T, Legrand F, Rassy EE,
Kaitouni MI, Albisinni S, Rousseau A, Vanhaeverbeek M, Rorive S,
Decaestecker C, Debeir O, et al: A prospective clinical study of
the implications of IL-8 in the diagnosis, aggressiveness and
prognosis of prostate cancer. Future Scie OA. 4:FSO2662017.
View Article : Google Scholar
|
|
35
|
Araki S, Omori Y, Lyn D, Singh RK,
Meinbach DM, Sandman Y, Lokeshwar VB and Lokeshwar BL:
Interleukin-8 is a molecular determinant of androgen independence
and progression in prostate cancer. Cancer Res. 67:6854–6862. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Ghotra VP, He S, van der Horst G, Nijhoff
S, de Bont H, Lekkerkerker A, Janssen R, Jenster G, van Leenders
GJ, Hoogland AM, et al: SYK is a candidate kinase target for the
treatment of advanced prostate cancer. Cancer Res. 75:230–240.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Prevo R, Pirovano G, Puliyadi R, Herbert
KJ, Rodriguez- Berriguete G, O'Docherty A, Greaves W, McKenna WG
and Higgins GS: CDK1 inhibition sensitizes normal cells to DNA
damage in a cell cycle dependent manner. Cell Cycle. 17:1513–1523.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Liu P, Kao TP and Huang H: CDK1 promotes
cell proliferation and survival via phosphorylation and inhibition
of FOXO1 transcription factor. Oncogene. 27:4733–4744. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Dunn GP, Old LJ and Schreiber RD: The
immunobiology of cancer immunosurveillance and immunoediting.
Immunity. 21:137–148. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Sava GP, Speedy HE, Di Bernardo MC, Dyer
MJ, Holroyd A, Sunter NJ, Marr H, Mansouri L, Deaglio S, Karabon L,
et al: Common variation at 12q24.13 (OAS3) influences chronic
lymphocytic leukemia risk. Leukemia. 29:748–751. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Suarez JS, Gurler Main H, Muralidhar GG,
Elfituri O, Xu HL, Kajdacsy-Balla AA and Barbolina MV: CD44
regulates formation of spheroids and controls organ-specific
metastatic colonization in epithelial ovarian carcinoma. Mol Cancer
Res. May 30–2019.(Epub ahead of print). doi:
10.1158/1541-7786.MCR-18-1205.
|
|
42
|
Miletti-González KE, Murphy K, Kumaran MN,
Ravindranath AK, Wernyj RP, Kaur S, Miles GD, Lim E, Chan R,
Chekmareva M, et al: Identification of function for CD44
intracytoplasmic domain (CD44-ICD): Modulation of matrix
metalloproteinase 9 (MMP-9) transcription via novel promoter
response element. J Biol Chem. 287:18995–19007. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Li W, Qian L, Lin J, Huang G, Hao N, Wei
X, Wang W and Liang J: CD44 regulates prostate cancer
proliferation, invasion and migration via PDK1 and PFKFB4.
Oncotarget. 8:65143–65151. 2017.PubMed/NCBI
|
|
44
|
Jiang L, Chan JY and Fung KP: Epigenetic
loss of CDH1 correlates with multidrug resistance in human
hepatocellular carcinoma cells. Biochem Biophys Res Commun.
422:739–744. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Sigismund S, Avanzato D and Lanzetti L:
Emerging functions of the EGFR in cancer. Mol Oncol. 12:3–20. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Hour TC, Chung SD, Kang WY, Lin YC, Chuang
SJ, Huang AM, Wu WJ, Huang SP, Huang CY and Pu YS: EGFR mediates
docetaxel resistance in human castration-resistant prostate cancer
through the Akt-dependent expression of ABCB1 (MDR1). Arch Toxicol.
89:591–605. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Ray K, Ujvari B, Ramana V and Donald J:
Cross-talk between EGFR and IL-6 drives oncogenic signaling and
offers therapeutic opportunities in cancer. Cytokine Growth Factor
Rev. 41:18–27. 2018. View Article : Google Scholar : PubMed/NCBI
|
